Skip to NavigationSkip to content

Top Ten most popular articles on this week!

Published on 07/06/19 at 10:57am

It was revealed this week that Pfizer suppressed findings that their anti-inflammatory Enbrel reduced the risk of Alzheimer’s by 64%. The revelation came as parents of children with cystic fibrosis clubbed together to form an Orkambi buyers club to import cheap generic versions of the drug into the UK.

Meanwhile tons of new data came out of the ASCO 2019 meeting as Janssen’s Imbruvica showed superiority over ofatumumab for leukaemia in Phase 3 trials. In other news the UK and others refused to sign up to a WHO resolution calling for greater transparency in drug pricing. For all of this and more, check out this week’s top 10!

10. First-of-its-kind data shows Novartis' iscalimab extends survival of transplanted kidneys

In a first-of-its-kind reveal, Novartis has presented histology data for iscalimab (CFZ533) at the American Transplant Congress (ATC) which indicates that the drug may be able to extend the survival of transplanted kidneys and improve the long-term outcomes of kidney transplant patients.

9. Janssen's Erleada combo smashes endpoints in advanced hormone-sensitive prostate cancer

Janssen joined the showing at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago to present new data for its androgen receptor (AR) inhibitor Erleada (apalutamide) in combination with androgen deprivation therapy (ADT) in the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)

8. Dr Dietmar Berger returns to big pharma

Industry veteran Dr Dietmar Berger has joined Sanofi as the company’s new Global Head of Development. Dr Berger joins the French firm after spending a year at US biotech Atara Biotherapeutics.

7. Parents of children with cystic fibrosis start Orkambi buyers club

Parents of children with cystic fibrosis have started an Orkambi buyers’ club to import generic versions of Vertex’s drug from Argentina into the UK.

6. Darzalex combo makes strong Phase 3 showing in multiple myeloma

Janssen has lifted the curtain on Phase 3 study findings for Darzalex  plus bortezomib, thalidomide and dexamethasone (VTd) before and after autologous stem cell transplantation (ASCT) in the treatment of newly diagnosed multiple myeloma.

5. UK government refuses to sign up to WHO pricing transparency resolution

The UK government has refused to sign up to a global resolution on transparency in drug pricing which urges governments to share information on the prices they pay for drugs.

4. Janssen's Imbruvica shows superiority in Phase 3 trials

Phase 3 data from ASCO 2019 has shown Janssen’s leukaemia drug Imbruvica (ibrutinib) had significant benefits over ofatumumab.

3. EMA approves Bluebird Bio's gene therapy Zynteglo

The European Commission has granted a conditional marketing authorisation to bluebird bio’s gene therapy Zynteglo.

2. Pfizer supressed research suggesting arthritis drug Enbrel reduced risk of Alzheimer's by 64%

Pfizer supressed data suggesting that their drug Enbrel reduced the risk of patients developing Alzheimer’s disease by 64%.

1. Biogen's diroximel fumarate impresses at Phase 3 in relapsing multiple sclerosis

New data for Biogen’s investigational therapy diroximel fumarate has been revealed at the Consortium of Multiple Sclerosis Centers (CMSC) in Seattle, supporting its safety and efficacy in the treatment of relapsing multiple sclerosis.


All these articles are great reads! Thanks. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches